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population. We typically recruit between 10–20 patients in which half the participants 
receive the ePRO ﬁ rst and the other half the paper version. Between administrations 
participants complete a distraction task. Interviews are recorded and a content analysis 
conducted to identify key issues. RESULTS: The mix of think-aloud and retrospective 
probing has worked well in a number of studies across disease areas to ensure equiva-
lence, high usability, and no unforeseen issues unique to ePRO such as screen glare 
or difﬁ culty holding a PDA device. Some patients have difﬁ culty with the “think-
aloud” approach and so the retrospective probing is a useful check against issues not 
spontaneously raised by the participant(s). CONCLUSIONS: Increased use of ePRO 
questionnaires necessitates a robust methodology for demonstrating equivalence 
during migration from paper versions. a mix of concurrent “think-aloud” and retro-
spective probing following completion of both PRO formats has shown to be a useful 
method for establishing validity of electronic outcome measures.
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OBJECTIVES: To examine item response patterns over time using the SF-12v2TM from 
a measurement perspective using US national representative samples. METHODS: 
Four panel data with two-year repeated measures on each respondent were extracted 
from the Medical Expenditure Panel Survey (MEPS). Respondents were included if 
they were ≥18 years, had completed SF-12v2TM and, had at least one of the top ten 
most prevalent health conditions identiﬁ ed using ICD-9-CM. Three-facet measurement 
model was used to parameterize time as a distinct facet in the model, in addition to 
person and item facets. Interactions between time and the twelve items were examined 
at each time point in all panels. Goodness-of-ﬁ t of the items to the model was exam-
ined in repeated measures as well as in point-in-time measures. INFIT mean-square 
(MnSq ≤ 1.40) was used as an item ﬁ t indicator. Cross-validations were conducted in 
each disease groups. RESULTS: Four panels were comparable in their distributions in 
health conditions, socio-demographics (mean ages were 52–53 years and, about 
76–77% were white) and, sample sizes (2003–04, n = 2,124; 2004–05, n = 2,070; 
2005–06, n = 2,148 and 2006–07, n = 2,329). Consistently in all panels, signiﬁ cant 
time and item interaction biases were found at time 1, especially on mental health 
items (P < 0.01). On the other hand, interaction biases between time and items at time 
2 were not signiﬁ cant (p > 0.05). All items ﬁ t the model in repeated measures where 
time was parameterized as a facet (INFIT MnSq ≤ 1.40). The mental health item “Have 
you felt calm and peaceful?” consistently showed misﬁ t in all point-in-time measures 
(INFIT MnSq > 1.40). Similar ﬁ ndings were noted in sub-samples. CONCLUSIONS: 
Findings from this study suggest consistent learned response patterns over time, 
especially the responses to mental health item, which give rise to the importance of 
inter-temporal health context in health measurement. Hence, cross-sectional health 
measures should be interpreted with caution.
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OBJECTIVES: Role functioning (RF) is a key component of social well-being and thus 
an important outcome in health research. The aim of this study was to calibrate on a 
common metric newly developed items assessing the impact of health on RF. The items 
were developed based on review of the literature and focus group interviews and were 
found to be sufﬁ ciently unidimensional for item response theory applications. 
METHODS: Two thousand ﬁ ve hundred participants completed a battery of measures 
including 77 items in a RF bank, covering the impact of health on family, occupational 
and social role functioning. Each new item covered only one of the content areas. 
Items were evaluated for potential DIF by demographic variables (gender, age, and 
chronic condition) using a logistic regression approach. To estimate the item param-
eters for each domain on a common metric we used the generalized partial credit 
model. Item ﬁ t was evaluated using the S-G2 index. Comparison of group mean bank 
scores of participants with different self-reported general health status and chronic 
conditions was used to test the external validity of the bank. RESULTS: After exclud-
ing items with DIF and poor ﬁ t the ﬁ nal item bank had a total of 64 items covering 
4 general content areas of role functioning (family, social, occupational, generic). 
Slopes in the bank ranged between 0.96 and 4.51; the mean threshold range was −0.66 
to −1.80. Item bank based scores were signiﬁ cantly different for participants with and 
without chronic conditions (F(4, 2488) = 31.48, P < 0.0001) and self-reported general 
health (F(4, 2488) = 233.55, P < 0.0001). CONCLUSIONS: An item bank assessing 
health impact on RF across 4 content areas has been successfully calibrated. Using 
computerized adaptive assessment, respondents will only need to answer items regard-
ing relevant roles, while IRT score estimation still allows for scoring all respondents 
on the same common metric.
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OBJECTIVES: The process of linguistic validation is complex especially when working 
with a variety of languages in widely divergent cultural settings. The ability to clearly 
delineate concepts and synchronize wording within an instrument before the linguistic 
validation process begins not only signiﬁ cantly improves the original instrument, but 
also aids in optimizing its translatability, ensuring greater uniformity between multiple 
linguistic adaptations and saving time and resources along the way. This paper seeks 
to explain the beneﬁ ts provided by the supplemental pre-translation process of face 
validation. METHODS: As part of a case study, face validated questionnaires were 
compared to the original homegrown versions of the corresponding instruments—
questionnaires that were already psychometrically validated were not eligible. Changes 
that were made as a result of this analysis will be discussed in-depth to clarify difﬁ cul-
ties that each issue would have created for the linguistic validation process had they 
not been corrected. a cost beneﬁ t-analysis was also conducted to conﬁ rm the value of 
this supplemental linguistic validation phase. RESULTS: While standard elements of 
the linguistic validation process, such as concept elaboration, international harmoniza-
tion, survey research expert review, in-country clinician review and cognitive debrief-
ing all assist greatly in creating a quality translation, none of their beneﬁ ts are a 
substitute for face validation. Furthermore, cost-beneﬁ t analysis reveals that the pre-
emption of linguistic or methodological issues prior to translation and the greater 
uniformity obtained amongst multiple translations created through face validation 
save time and money later on in the linguistic validation process, justifying the added 
up-front costs. CONCLUSIONS: As the case studies conﬁ rm, taking steps to maximize 
the translatability of a questionnaire prior to linguistic validation, through face valida-
tion in particular, is highly beneﬁ cial to the end-products and can also hasten overall 
project completion and improve the quality of all language versions of the 
instrument.
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OBJECTIVES: ClinROs are the most commonly observed endpoint in FDA approved 
product labels but few have been adequately scrutinized in terms of their suitability 
as endpoints. This study evaluates two widely used ClinROs (the Expanded Disability 
Status scale (EDSS), and the Hamilton Rating scale for Depression (HAM-D)) and 
provides an assessment on how migrating the measures onto an electronic platform 
might be able to improve their validity and reliability. METHODS: A literature review 
was conducted on both measures to evaluate the availability of information on their 
content validity and reliability and validity. An assessment was made on how the 
measures could be improved if they were to be migrated onto an electronic platform: 
RESULTS: The EDSS has shown varying results for validity and inter-rater reliability 
and it involves a complex scoring procedure. The migration of the EDSS onto an 
electronic format would enable an automated scoring system which could improve its 
validity. The HAM-D was found to be lacking in evidence of content validity and to 
have some complexity in the scoring system. Transferring the HAM-D onto an elec-
tronic platform could simplify the scoring system which could improve its validity. 
CONCLUSIONS: This study has highlighted some of the issues with validity and 
reliability of two widely used ClinROs. The migration of ClinROs to an electronic 
platform in addition to the ePRO migration cognitive debrieﬁ ng and usability testing 
might go some way to improving the clarity of ClinROs which may go some way to 
improving the validity of the measures. It cannot however resolve all of the issues such 
as lack of content validity and its impact would vary widely according to the complex-
ity of the ClinRO itself.
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OBJECTIVES: This analysis describes the development, application and comparison 
of three different approaches to evaluate measurement equivalence properties of a 
patient reported outcome (PRO) questionnaire applied to two treatment groups for 
gastroesophageal reﬂ ux disease (GERD). The data used in this analysis was obtained 
from an on-line patient community, iGuard.org. Patients using either of the two treat-
ments were randomly invited to complete a measure of treatment satisfaction, the 
Treatment Satisfaction Questionnaire for Medication (TSQM). METHODS: Three 
statistical approaches were used to evaluate the measurement equivalence of the 
TSQM across the two patient populations: 1) Classical Test Theory (CTT) to assess 
the internal consistency of the TSQM items within each of the three factors using 
Cronbach’s alpha; 2) Conﬁ rmatory Factor Analysis (CFA) using a special case of 
structural equation modelling (SEM); and 3) Item Response Theory (IRT)—based 
technique of Differential Item Functioning (DIF). RESULTS: All three statistical 
methods indicated measurement equivalence had been achieved across the two treat-
ment populations for all the three domains of the TSQM. The effectiveness and global 
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satisfaction domains exhibited the strongest signiﬁ cant results amongst all three tests. 
However, while the convenience domain exhibited strongly signiﬁ cant measurement 
equivalence for the CTT, it only exhibited signiﬁ cant results for the SEM and DIF. 
CONCLUSIONS: While all three methods indicated the same overall results, there is 
some suggestion of differing sensitivity amongst the tests.
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OBJECTIVES: Delivering care coordination services is often described as the key to 
effectively meet patients’ needs and expectations. Patient empowerment and patient 
participation is highly discussed and postulated, but there is a lack of knowledge of 
how to design patient-centered coordinated care. This study intends to provide health 
policy and decision-makers with a comprehensive assessment on experts’ priorities in 
the relative value of different dimensions of coordinated care. METHODS: A ques-
tionnaire with 88 items was conducted with N = 251 health care experts. Exploratory 
and conﬁ rmatory factor analysis was performed using SPSS©18. The number of factors 
to be retained was controlled by Kaiser’s criterion (eigenvalues above 1), validation 
of the scree plot, and the interpretability of the items. Cronbach’s alpha was used to 
assess the internal consistency of the subscales identiﬁ ed. RESULTS: The exploratory 
factor analysis leaded to 25 factors. After analyzing the screeplots and qualitative 
results conﬁ rmatory factor analysis was computed for an 8 factor solution accounting 
for 42,828 % of the total variance and with KMO of 0.723. Cronbach alpha reliability 
coefﬁ cients were computed for each of the sub-scales and ranged between 0.849 and 
0.745. Based on the existing literature and the analysis conducted, coordinated care 
could be differentiated into eight dimensions: access, knowledge transfer, technical 
care, interpersonal care, patient-centeredness, continuity, infrastructure and participa-
tion in social life. CONCLUSIONS: The aim of the study was to structure the key 
attributes for future stated preference research. Differences in experts’ judgment and 
patients’ perspective will be analyzed in upcoming research. If expectations of stake-
holders are taken into account adequately, it can be assumed that this will increase 
the motivation to participate in and the satisfaction with coordinated care 
programs.
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OBJECTIVES: While eClinical Forum’s 2009 survey ﬁ ndings suggest that electronic 
data capture (EDC) is used in 58% of clinical trials, little is known about the use of 
electronic patient reported outcome (ePRO) technologies for data collection. The 
purpose of this survey study was to describe the experiences and perceptions regarding 
use of ePRO as reported by pharmaceutical, biotech, medical device, and other indus-
try professionals. METHODS: Global industry professionals were invited to complete 
a web-based survey ﬁ elded in early 2010. Participants were asked about their profes-
sional demographics, PRO and ePRO experiences, as well as challenges and advan-
tages of using ePROs. Responses were analyzed descriptively. RESULTS: To date, 153 
industry professionals completed the survey. Forty-four percent of respondents were 
from pharmaceutical companies, followed by other (41%), biotech (10%) and medical 
device (6%). Forty nine percent had previous PRO study experience among which 
51% had prior ePRO experience. Among respondents using a PRO measure in an 
international study, 43% used ePRO for data collection. Hand-held device (tablet, 
PDA) was the most common ePRO technology (42%), followed by interactive web-
response (29%) or voice-response (29%). Reported advantages of ePROs include 
accuracy of information collected (79%), increased compliance (73%), and ease of 
use (64%); challenges include patient training (65%), study start-up costs (64%) or 
time (54%), and patient burden (54%). Validation of PRO for EDC use was an 
important factor when considering paper-based versus ePRO data collection (21%). 
Among those responding, 26% indicated they used ePRO data collection in >50% of 
their clinical trials, and 82% strongly agreed/agreed they would use ePRO in future 
studies. CONCLUSIONS: Preliminary results from this survey suggest that among 
those who use PRO measures in studies, the percent of industry professionals using 
ePROs is similar to the overall percent of industry using EDC as a data collection 
method in clinical trials.
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OBJECTIVES: PRO measures use a variety of response scales/options. These vary 
according to the type of measure, and can include frequency (time-based) scales, 
severity (intensity) scales, visual analogue scales (VAS) and levels of agreement. The 
translation and linguistic validation of response options can cause semantic or con-
ceptual difﬁ culties. This research aims to identify the issues raised during the transla-
tion of some response scales, with the aim of aiding the translatability of response 
options. METHODS: Examples of issues in the translation and linguistic validation 
of response options were collected from past Oxford Outcomes projects. Those 
response options which were problematic across PRO measures and languages were 
evaluated. RESULTS: Numerous cultural and linguistic issues became apparent 
throughout the translation process which require careful attention being paid to the 
response options during the translation and linguistic validation process: /Some mid-
scale words used in severity scales are particularly difﬁ cult to translate, e.g. rather, 
somewhat. Two response options on a scale, e.g. rather conﬁ dent, fairly conﬁ dent can 
be very small and unclear. /Frequency scales (how often . . .) are often translated as 
“how many times,” in some languages (particularly Indian). When using “level of 
agreement” scales the word “strongly” often proves problematic as some languages 
ﬁ nd it difﬁ cult to express levels of agreement. CONCLUSIONS: Various issues with 
response options were recognised during the linguistic validation of a considerable 
number of PRO measures. a full translation and linguistic validation procedure can 
help to overcome such problems, but care should be taken when choosing response 
scales during the development of PRO measures. In general, response options, which 
are particularly close in meaning, e.g. somewhat, rather, are usually more problematic 
to translate than those with clear parameters, e.g. never, rarely, sometimes, often, 
always.
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OBJECTIVES: Capturing patient-reported outcomes (PRO) via the web can be an 
efﬁ cient tool in larger-population clinical studies. Enabling patients to use their own 
computers means that web-based PROs are administered to patients on a wider variety 
of screen sizes and resolutions. As indicated in the recent ISPOR ePRO Report by 
Coons SJ, et al, this creates an issue of ensuring equivalency of the instruments across 
all screen sizes. This research describes a practical approach for maintaining validity 
of instruments when patients use their own computer. It aims to evaluate whether the 
PRO is presented as intended on various screen sizes and browsers. The research also 
takes into consideration variability of computer infrastructure in different geographi-
cal areas, as this is a major factor limiting web-based data collection. METHODS: 
The EuroQoL EQ-5D was programmed for use on smaller screens and scaled up to 
larger sizes and put into an ongoing usability testing study in the US, UK, Spain, 
Finland, Singapore, and China for sufﬁ cient coverage of languages and technologies. 
The sample size is 30 healthy volunteers. Screen sizes varied from small mini laptop 
screens to large LCD screens (9″ to 24″). RESULTS: Early results show that the 
questionnaire ﬁ ts on all screens without a need for patients to scroll either in left-right 
or up-down directions. On 15,4″ screen, the questionnaire occupies 71% of the screen 
versus 57% on a 24″ display. The difference in relative size is 19%, which indicates 
that the questionnaire remains usable even if the screen size increases by 56%. Further 
results are forthcoming. CONCLUSIONS: As the presentation of the PRO is the same 
on all screens, conducting psychometric validation may be more straightforward. In 
addition, ﬁ nding a method to ensure one PRO design works on all computers is a 
major factor in conducting global studies efﬁ ciently.
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OBJECTIVES: In clinical trials, the capture of patient-reported outcome (PRO) data 
has increased over the past decade. Regulatory guidelines, including the EMEA’s 
concern of Health-Related Quality of Life (HRQL) measurements and the FDA’s 
emphasis on PRO data to support labeling claims, have led to a greater inclusion of 
PRO as clinical trial endpoints. As sponsors include more PRO measurements, many 
turn to electronic PRO (ePRO) data capture. This presentation summarizes literature 
from the last 9 years to report changes in the use of ePRO including projections for 
future applications in clinical trials, disease management and health policy. 
METHODS: This presentation is a synthesis of literature in peer reviewed journals 
regarding ePRO from 2000 to 2010. Key search terms include “patient reported 
outcomes”, “electronic patient reported outcomes”, “electronic diaries”, “interactive 
voice response system”, “interactive web response system” and “digital pen”. The 
literature review made use of meta-databases such as PubMed and Medline. RESULTS: 
The use of ePRO has increased since a decade ago, due to greater movement in health 
care towards electronic solutions and to regulatory emphasis on PRO collection in 
clinical trials. The presentation will detail how ePRO is being used and provide a 
synthesis of recommendations for future ePRO use based on the literature. The session 
will examine the indications and therapeutic areas, population types, and applications 
of ePRO within health care and will review evidence showing whether ePRO data 
quality is higher than that of data captured using paper methods. CONCLUSIONS: 
The presentation deals with the evolving questions of ePRO—projected limitations and 
actual scope of experience with ePRO. Due to literature emphasis, the presentation will 
focus on clinical trials but will also examine other health care ﬁ elds such as disease 
management and health policy. Attendees will learn about the evolution of ePRO and 
forthcoming directions and receive a bibliography of current literature.
